about
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).Face-name memory training in subjective memory decline: how does office-based training translate to everyday situations?Reduced Benefit of Memory Elaboration in Older Adults with Subjective Memory Decline.Relationship between control beliefs, strategy use, and memory performance in amnestic mild cognitive impairment and healthy aging.Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging.Naturalistic prospective memory in older adults: Predictors of performance on a habitual task.The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease.Olfactory deficits and amyloid-β burden in Alzheimer's disease, mild cognitive impairment, and healthy aging: a PiB PET study.Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.Relationship between atrophy and beta-amyloid deposition in Alzheimer disease.Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia.Larger temporal volume in elderly with high versus low beta-amyloid deposition.Memory profiling with paired associate learning in Alzheimer's disease, mild cognitive impairment, and healthy aging.Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging.Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.Is the WMS-IV verbal paired associates as effective as other memory tasks in discriminating amnestic mild cognitive impairment from normal aging?Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.Imaging beta-amyloid burden in aging and dementia.Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer's disease.Amyloid imaging in Alzheimer's disease and other dementias.Strategies for improving memory: a randomized trial of memory groups for older people, including those with mild cognitive impairment.Naturalistic measures of prospective memory in amnestic mild cognitive impairment.Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.Clinical measures of prospective memory in amnestic mild cognitive impairment.Names and numberplates: quasi-everyday associative memory tasks for distinguishing amnestic mild cognitive impairment from healthy aging.Knowledge and use of memory strategies in amnestic mild cognitive impairment.Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease.Bridging the gap between clinical trials and community care: Translating a memory group for older people with mild cognitive impairment into a community-based organisationWho benefits from cognitive intervention in older age? The role of executive function
P50
Q33884978-DCEB3878-6478-457B-9912-89BF80DE4704Q34606557-81027D54-53AF-44C1-B844-C3E8054AF548Q38164141-7508953B-CE27-41F6-BA5B-8E2357A90DE8Q38371870-1AF5FB42-4362-46B2-B0F8-704B0C1AF879Q38403238-3404F167-6E76-47E4-BF27-0971EC617366Q38453545-3668978A-13F7-4402-9B82-717A254A237AQ38484728-2C9A5A55-6D52-4B90-804B-0C9EFE9C56AFQ38798780-8D118393-9372-4984-98DB-B54BCEA0D0BDQ39976878-E6EBDABE-65DA-49B2-9DED-39138F129BF5Q42866937-B4AABE33-1A83-41D8-8DF3-6259D2D306DBQ43062420-8AA4ED9B-438D-4A1E-B645-2DC8795833E2Q43107490-004CD45D-7A18-404A-9B00-6158DFF8E9A5Q43197308-5D888F0D-E317-41B5-95DD-A5654A24E649Q43965311-3933BED8-57A4-4A0A-B2AC-4DA5DA352AC0Q46185406-FFD23A23-7D86-47CF-A703-102374450C36Q46370277-D650697B-94F3-4A84-9379-C8BEBD45011CQ46810913-6554D588-16BD-4666-BD05-97F3101109E7Q46854974-991AE103-14F0-47DE-8353-E855D4CE795FQ46956885-52B1E60F-89BC-4A82-80DA-1B9BD49B429AQ48168226-60A764A7-5C7D-4AEA-B55C-06DB8C9605A2Q48211669-1D5B3A7D-DBDD-4CFC-8D9D-FAAE0605530EQ48325860-A64FC480-6764-4F28-A4F9-50E2604C0502Q48473310-D1D78B42-943F-4D08-B2BC-9D73310B2FCFQ50556797-81DA3841-0BFC-4A1A-8B7B-2E11F8A38935Q50788300-7AD06AE5-28AF-4B93-BEF8-23C4C8EA43C4Q50863895-232373E9-B4B9-4B9D-B698-FCA347A458D2Q50971945-3DF32853-6DDB-4A27-98AA-2684945AA7F1Q50974820-77DFAC75-4345-4656-8B67-05A50D47BF12Q50980810-78A1A349-09AC-4548-A410-197B69850481Q51020301-031AC06B-631C-4F68-8183-F3F1595FC71BQ51966335-61E45F28-995B-4AF2-84D9-A7E2D76EDB21Q90157923-BA26B6BC-F8E1-4CC8-BBCD-E8D75C0F0F0CQ91870762-AB96B76E-4943-4F47-ABC4-3D354444A664
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kerryn E. Pike
@ast
Kerryn E. Pike
@en
Kerryn E. Pike
@es
Kerryn E. Pike
@nl
Kerryn E. Pike
@sl
type
label
Kerryn E. Pike
@ast
Kerryn E. Pike
@en
Kerryn E. Pike
@es
Kerryn E. Pike
@nl
Kerryn E. Pike
@sl
prefLabel
Kerryn E. Pike
@ast
Kerryn E. Pike
@en
Kerryn E. Pike
@es
Kerryn E. Pike
@nl
Kerryn E. Pike
@sl
P106
P1153
22951577700
P31
P496
0000-0002-0474-1215